SCHEMBL5258133

SCHEMBL5258133

O=C(CCCCO)c1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
CTNNB1 P35222 4/20 0.52
WNT3A P56704 4/20 0.52
PARP1 P09874 1/20 0.50
MAPT P10636 4/20 0.49
LMNA P02545 3/20 0.49
NPC1 O15118 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 3/20 0.49
HTT P42858 3/20 0.49
MEN1 O00255 2/20 0.49
TSHR P16473 2/20 0.49
KMT2A Q03164 2/20 0.49
ALOX12 P18054 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5258130 0.86 CES2 (0.53) CES2CES1CTNNB1WNT3APARP1
SCHEMBL28922045 0.85 CES2 (0.52) CES2CES1CTNNB1WNT3APARP1
SCHEMBL7387888 0.85 MAPT (0.52) CES2CES1CTNNB1WNT3APARP1
SCHEMBL5660149 0.85 CES2 (0.52) CES2CES1CTNNB1WNT3APARP1
SCHEMBL5663318 0.83 CTNNB1 (0.50) CES2CES1CTNNB1WNT3APARP1
SCHEMBL8846361 0.83 HDAC1 (0.58) CES2CES1CTNNB1WNT3APARP1
SCHEMBL7648015 0.83 CES2 (0.53) CES2CES1CTNNB1WNT3APARP1
SCHEMBL29508072 0.83 HTR7 (0.64) CES2CES1CTNNB1WNT3APARP1
SCHEMBL3022950 0.83 CES2 (0.53) CES2CES1CTNNB1WNT3APARP1
SCHEMBL7401046 0.81 L3MBTL1 (0.55) MAPTLMNANPC1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1221440-B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators OTSUKA PHARMA CO LTD (JP) 2007-04-25 EP disclosed
US-6642223-B2 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
EP-1221440-A1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators Otsuka Pharmaceutical Company, Limited (JP) 2002-07-10 EP disclosed
US-20020049194-A1 Benzoheterocyclic derivatives OGAWA HIDENORI (JP) 2002-04-25 US disclosed
US-6335327-B1 Benzoheterocyclic derivatives OTSUKA PHARMACEUTICALS CO., LTD. (JP) 2002-01-01 US disclosed
US-6096735-A Benzoheterocyclic derivatives OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-01 US disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
WO-1995034540-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049194-A1 Benzoheterocyclic derivatives AVPR2, AVPR1A, AVPR1B CES2 3686/4885CES1 3079/4885CTNNB1 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.